Definium Therapeutics (DFTX) Return on Capital Employed (2022 - 2026)

Definium Therapeutics (DFTX) has 5 years of Return on Capital Employed data on file, last reported at 56.94% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 56.94%, down 1285.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 56.94% (down 1285.0% YoY), and the FY2025 annual result was 54.63%, up 492.0% from the prior year.
• Return on Capital Employed grew to 56.94% in Q1 2026 per DFTX's latest filing, from 61.19% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 3.1% in Q3 2022 and troughed at 93.12% in Q4 2023.
• A 5-year average of 48.7% and a median of 49.54% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 8042 bps in 2023, then jumped 5493 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 42.1% in 2022, then slumped by 121 bps to 93.12% in 2023, then jumped by 59 bps to 38.19% in 2024, then slumped by 60 bps to 61.19% in 2025, then gained by 7 bps to 56.94% in 2026.
• Business Quant data shows DFTX's Return on Capital Employed at 56.94% in Q1 2026, 61.19% in Q4 2025, and 81.47% in Q3 2025.